posted
The most recent annual report, and if applicable, quarterly report, is available for BioNeutral Group, Inc.Font size: A | A | A3:16 AM ET 8/16/09 | Dow Jones BioNeutral Group, Inc.: The most recent annual report, and if applicable, quarterly report, is available at no fee.
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/nae/al?rnd=tUV%2FQW%2FEgBD9cha%2B9EypXw%3D%3D. You can use this link on the day this article is published and the following day. This was on etrade, why wouldn't they just post their earnings???????
NEWARK, N.J., Aug 24, 2009 (BUSINESS WIRE) -- BioNeutral Group, Inc. ("BioNeutral") (BONU, Trade ), a specialty chemical technology based Life Science Company, announced discussions with four of the world's largest health care companies. The discussions included both scientific and business representatives all interested in BioNeutral's game changing technology - "Sporicidal performance on surfaces and skin." Game changing technology is an infrequent occurrence. However, it is easy to identify and differentiate from the run of the mill or obsolete technology and thus generates intense interest. BioNeutral is in a unique position in that it has not solicited contacts with major players in the antimicrobial and health care arena; instead these well known companies have been contacting BioNeutral to develop partnering relationships.
Any antimicrobial which is not sporicidal may be a carrier for the dangerous and difficult to kill organisms which may then be transported from person to person (this includes all known alcohol, silver or quat based formulations). For example, Clostridium Difficile spores are associated with hospital acquired infections which results in diverted heath care provider's efforts, millions of dollars in extra expenses and hundreds of thousands of unnecessary deaths annually in the US alone. The best high powered currently used hospital disinfectants based upon quaternary ammonium compounds, silver based disinfectants or alcohol washes are totally ineffective at eradicating Clostridium Difficile (C-diff) spores, resulting in a serious unmet need in the health care arena. BioNeutral's Ygiene(TM) is the clear solution for this serious problem.
Dr. Andy Kielbania, Chief Scientist at BioNeutral Group stated, "Results of in-house testing conducted this past week demonstrated a 30 second kill time for the most difficult to kill spores with a mild formulation that is gentle to skin, surfaces and fabric. These are the best results we have produced thus far."
"When these results are confirmed by independent testing," said one of the health care executives, "It represents a game changer which will determine control of a worldwide antimicrobial health care market."
BioNeutral Group Inc. CEO, Stephen J. Browand, stated, "If game changing technology were presently out there, we would not be inundated with calls from the major players in the healthcare field. Killing low level microorganisms with old, me too technology (alcohol, silver, quats or bleach) has been available for quite some time. Rapidily eliminating dangerous spores such as Clostridium Difficile (C-diff) with our new mild Ygiene(TM) formulation which can be exposed to skin is considered the holy grail of antimicrobial performance. Independent lab testing confirming last week's R&D breakthrough should take approximately three weeks".
BioNeutral Group Inc. has confirmed independent test results which indisputably show the Company's Ygiene(TM) formulations outperform virtually all antimicrobials available when it comes to difficult to kill, dangerous organisms including black mold. Dissimilar to silver, bleach and quat based older technology; BioNeutral's Ygiene(TM) is non corrosive, non-staining, non flammable and completely sporicidal.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and Chemo Neutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
SOURCE: BioNeutral Group, Inc.
BioNeutral Group Inc. Stephen J. Browand, President and CEO steve*bioneutralgroup.com or Investor Relations Aimee Boutcher, 973 239-2878 aboutcher*aol.com
I got in last week too - at .43 - Why can't I pick one that just keeps running and running? I was up $2,000 an hour ago - was down to being up 1,200 or so last time I looked. Good luck to us all .....
Did you see this news from the Gov't. this morning:
Swine Flu Could Cause 90,000 US DeathsCNN posted:
5 HOURS 19 MINUTES AGOcomments: 363filed under: Health News, National News
(Aug. 24) -- The H1N1 flu virus could cause up to 90,000 U.S. deaths, mainly among children and young adults, if it resurges this fall as expected, according to a report released Monday by a presidential advisory panel. The H1N1 virus, commonly known as swine flu virus, could infect between 30 percent and 50 percent of the American population during the fall and winter and lead to as many as 1.8 million U.S. hospital admissions, the President's Council of Advisors on Science and Technology reported. Skip over this content
posted
BioNeutral Group Receives Legal Opinion on the Manufacture and Sales of Ygiene(TM) in the United Kingdom, France and Sweden; Ygiene(TM) Passes Another Key GLP Test in US Last update: 4/19/2010 11:11:00 AM Three Countries Could Join Germany as First European Markets for Hospital-Grade Antimicrobial Product NEWARK, N.J., Apr 19, 2010 (BUSINESS WIRE) -- BioNeutral Group, Inc. (BONU), a specialty chemical technology-based life science company, reports that it has received legal opinion on the manufacture, marketing and sales of the hospital-grade formulation of its antimicrobial Ygiene(TM) in the UK, France and Sweden. The Company has previously received permission to market Ygiene(TM) in Germany as noted in its most recent 10K filing, potentially bringing to four the number of European markets for the new product. Further, BioNeutral has received test results from ATS Labs indicating that its Ygiene(TM) Antimicrobial has passed the stringent GLP test requirements for hospital and medical environment efficacy claims. This key test was also performed in the presence of protein, which indicates there is no need to clean surfaces before disinfecting, thereby eliminating harmful microorganisms in 2 minutes or less. According to a memorandum prepared by BioNeutral's attorneys, Edwards Angell Palmer & Dodge (EAPD), in the UK, the Company is currently entitled to manufacture, market and sell Ygiene(TM) through May 2014 throughout the European Union provided that it complies with the requirements of each member state. The legal team advised the Company that the UK, France and Sweden require only basic notification to the national authorities before sales of Ygiene(TM) could commence within each of these countries. BioNeutral was also informed that sales within eleven additional EU nations would require formal applications to be submitted to the appropriate authorities. "As BioNeutral seeks to expand its product sales across Europe, it is first necessary that we carefully evaluate the requirements of each EU member state with regard to the marketing of biocides," said Stephen J. Browand, President and CEO of BioNeutral Group. "The opinion we have received from our UK legal team indicates that the UK, France and Sweden can quickly join Germany in becoming the next European markets for Ygiene(TM), a development that would significantly boost our potential global market presence". With regard to the GLP test in America, Dr. Andrew Kielbania, Chief Scientist at BioNeutral, stated: "Passing this difficult hospital disinfectant test along with the other GLP tests is a key result. Individuals that are using disinfectants usually do not know what harmful microorganism they are dealing with. Our goal at BioNeutral is to deliver a unique and effective broad spectrum antimicrobial that will eliminate health threatening microorganisms in one short contact time. This will insure a high level of disinfecting and will eliminate end user confusion and uncertainty." In addition to a variety of virus strains, Ygiene(TM) has been proven to kill spores, including the difficult to eradicate C. difficile and anthrax spores. Ygiene(TM) does not stain clothes or fabric and breaks down into materials that are not harmful to the environment
posted
Yea ! I remember last fall (September/October, 2009) when this one was smoking all the way to $2.75/share at one time and I made money and was happy.I am sure begining this allegies season up to flu season and given positive news releases like what we saw today, it will pick itself up gradually and run northwards in my opinion. Goodluck to all participants (Investors)this time around. Hopefully it runs northwards.
IP: Logged |
posted
BioNeutral Group Signs LOI with Germany's ANA Aquiline Ltd. Last update: 4/29/2010 8:30:58 AM German Product Manufacturer Focuses on Bioneutral's Line of Superior Antimicrobials NEWARK, N.J., Apr 29, 2010 (BUSINESS WIRE) -- BioNeutral Group, Inc. (BONU), a specialty chemical technology-based life science company, reports that it has signed a Letter of Intent (LOI) with ANA Aquiline Ltd., a European manufacturer of cleaning cloths and sponges, to integrate BioNeutral's line of antimicrobials, including Ygiene(TM) and Ogiene(TM), into its versatile toweling system and to market and sell the resulting products in both the institutional and retail sector within Germany and the United Kingdom. ANA Aquiline Ltd., 30-year-old private company headquartered in Germany, markets a wide variety of consumer and industrial products designed for use in the cleaning and care of a range of surfaces, fixtures, kitchenware and other items. The LOI states that BioNeutral and ANA Aquiline intend to conclude a binding agreement on or before June 28, 2010. Stephen J. Browand, President and CEO of BioNeutral, stated: "The wide variety of uses of ANA Aquiline's superior-quality towel products is impressive. At this stage, we have just started to evaluate the prospects of a business relationship; however, in the event an agreement is finalized, we would look forward to implementing our versatile antimicrobial line into ANA Aquiline's products and giving consumers in Germany and the UK a chance to reap the benefits of their use." About ANA Aquiline Ltd. Headquartered in Merenberg, Germany, ANA Aquiline Ltd. is a 30-year-old manufacturer and marketer of high-quality cleaning cloths and sponges for consumer and industrial use. The company currently oversees the production of more than 50 products including all-purpose cloths and wipes, scourers and sponges, microfiber cloths, glass and window cleaners, floor cleaners, dusting cloths, car care cloths, and skin care items. For more information, please visit About BioNeutral Group, Inc. Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a speciality chemical technology-based Life Science company that is developing and intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are both eco-friendly. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene(TM) brand have not yet been submitted to the EPA for approval for sale in the United States, however they have been approved in Germany & are allowed in the UK, France & Sweden.
posted
BioNeutral Group Passes Final Key GLP Efficacy Test for Registration as a Hospital Sporicide in Canada and Australia Last update: 5/3/2010 9:27:00 AM BioNeutral's Ygiene(TM) Passes the Difficult Sporicide Test in Only 20 Minutes, Thus Completing the GLP Test Requirements for Product Approvals NEWARK, N.J., May 03, 2010 (BUSINESS WIRE) -- BioNeutral Group, Inc. (BONU), a specialty chemical technology-based life science company, reports that it has received test results from ATS Labs indicating that its Ygiene(TM) hospital-grade antimicrobial has passed the stringent sporicidal GLP test requirements for hospital and medical environment sporicide efficacy claims in Canada and Australia. This key test demonstrated that Ygiene(TM) hospital-grade antimicrobial eliminated harmful spores in only 20 minutes. With the completion of the required GLP testing, BioNeutral is now positioned to apply for approval of its Ygiene(TM) hospital-grade antimicrobial as a bactericide, fungicide and sporicide with Health Canada under the Food and Drug Act (see ) and in Australia with the Department of Health and Aging Therapeutic Goods Administration (see ). BioNeutral Group intends to proceed with these approvals and commercialize Ygiene(TM) hospital-grade antimicrobial in these countries. Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated: "We are extremely pleased with these test results for Ygiene(TM), which show that we have a rapid-acting sporicide. We look forward to entering the important markets of Canada and Australia in addition to Germany and the United Kingdom."
posted
BioNeutral Group Signs Agreement to Acquire Steri-7 Last update: 5/18/2010 8:00:13 AM Combined Product Formulations to Offer an Intergraded Disinfecting Solution for International Distributors, Health Care Providers, Industrial and Institutional Customers, and Consumers NEWARK, N.J., May 18, 2010 (BUSINESS WIRE) -- BioNeutral Group, Inc. (BONU), a specialty chemical technology-based life science company, announced today the signing of an agreement to acquire all of the shares of Steri-7, a UK manufacturer and supplier of proprietary formulations in the disinfectant and cleaning field with sales in Europe and the Middle East. Steri-7 and BioNeutral technologies offer consistent performance claims for worldwide solutions in the health care and related fields. The parties hope to finish documentation by the end of May and close by the end of July. Terms and conditions are being held confidential. Steri-7 has sales of approximately one million pounds for this fiscal year and currently offers products for the hospital, nursing home, physician office, police department and equine market in the UK and Europe. Sales have commenced utilizing some of the largest distributors on the continent. Steri-7 and BioNeutral technologies are designed to meet health regulatory requirements in all major markets around the world, offering opportunities and solutions for international distributors to maintain consistent claims and market more effectively. Jim Fraser, CEO of Steri-7 said: "We are concentrating on Europe and the Middle East, with the best formulations on the market. Our business is growing very fast and it will be exciting to serve large international distributors with an intergraded product line. Bioneutral technology will open up the US and related markets with an overall product line that will create a large successful company." Nick Sayer, Managing Director Worldwide for Steri-7 said: "7 is approved by the NHS here in the UK and our distributors are doing quite well with our products. Our Steri -- 7 line shows sporicidal results for up to 7 days and we are excited about the prospects of becoming the gold standard in the industry. We just launched our new Equine product line in the US. It works well enough for the Queen's horses and the Aga Kahn as their stables now use Steri-7." Andy Kielbania, Chief Scientist for Bioneutral, said: "Both of the technology platforms, BioNeutral and Steri-7, can jointly help us create a class of super-products that vastly outperform competing products on the market." Stephen J. Browand, President and CEO for Bioneutral, said: "This acquisition is designed to produce technologies that can give rise to even better products in the future, while meeting the two regulatory systems--those in the US and the UK--that are adopted by most countries of the world. Large players in the health care and related markets are global, and we believe that this combination of products will be very appealing to a wide range of customers." About BioNeutral Group, Inc. Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a specialty chemical technology-based life science company that is developing and intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous microorganisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), are both eco-friendly. The Company has combined these widely used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene(TM) brand have not yet been submitted to the EPA for approval for sale in the United States; however they have been approved in Germany and are allowed in the UK, France and Sweden. More information about the Company may be found at About Steri-7: Steri-7 is a privately held UK company with a broad product line of advanced proprietary antimicrobial formulations designed to eliminate bacteria, virus and spores in the health care and related industries with products which include sporicidal hard surface sprays, sporicidal wipes and sporicidal hand cleansers. All products are mild, environmentally friendly and provide long-lasting protection which is unique in the industry. Sales have commenced in the UK and the Middle East.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
